Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Johnson & Johnson (NY:JNJ)

259.36 UNCHANGED
Delayed Quote Updated: 7:00 PM EDT, Oct 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
2 Dividend Stocks Crushing the Market in 2026 (and Which Ones Can Keep Going) ↗
These drugmakers are facing some near-term challenges, but is that enough to stop their recent momentum? 
Via The Motley Fool
Dow Jones Top Gainers on Oct. 20, 2026: MMM, UNH, MRK Lead Session ↗
Via Chartmill
Topics Stocks
News headline image
What a Mixed Midterm Result Could Mean for These 2 Health Care ETFs ↗
Polls suggest a divided government after the midterms, a scenario that historically benefits healthcare stocks. Here's how the XLV and IHF ETFs compare for investors eyeing the sector. 
Via MarketBeat
Topics ETFs
News headline image
Should You Invest in This Dividend King on the Dip? ↗
Looking beyond near-term headwinds paints a fairly bright picture of Johnson & Johnson’s outlook. 
Via The Motley Fool
Johnson & Johnson (NYSE:JNJ) Q3 2026: In-Line Results and Raised Guidance Offset by MedTech Weakness ↗
Via Chartmill
News headline image
When the Stock Market Gets Dangerous, These 6 Investments Have a History of Holding Up ↗
These companies generate resilient revenues, which help make their stocks less volatile during market downturns. 
Via The Motley Fool
Topics Economy
News headline image
MarketBeat Week in Review – 10/12 - 10/16 ↗
Tech stocks fell on inflation fears and AI infrastructure concerns while the Dow rose, as MarketBeat analysts review earnings outlooks, sector rotation, and stock picks from the week's top stories. 
Via MarketBeat
Topics Artificial Intelligence Economy Stocks
News headline image
Johnson & Johnson Just Raised Its Sales Outlook Again. Here's Why the Dividend King Is Still a Buy. ↗
The guidance bump doesn't matter nearly as much as investors' response to the company's Q3 report suggests. 
Via The Motley Fool
News headline image
If a Stock Market Crash Is Coming, History Says These 3 ETFs Are the Smartest Buys ↗
These funds can help you weather any storm that might be on the way. 
Via The Motley Fool
Topics ETFs Stocks
News headline image
Bristol-Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026? ↗
Bristol-Myers trades at a significant valuation discount, but its higher leverage and patent risks contrast sharply with Johnson & Johnson's diversified stability. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Johnson & Johnson: 3 Key Takeaways for Long-Term Investors ↗
MedTech growth stalled while pharma surged, leaving the company to bet on new product launches and a planned spin-off to restore momentum. 
Via The Motley Fool
Topics Earnings
News headline image
This Unstoppable Vanguard ETF Could Turn $500 Per Month Into $1 Million Over the Long Term ↗
This exchange-traded fund consistently outperforms the S&P 500 thanks to its concentrated portfolio of growth stocks. 
Via The Motley Fool
Topics Artificial Intelligence ETFs Economy
Discover which dow jones stocks are making waves on Thursday. ↗
Via Chartmill
News headline image
Meet the Low-Cost Vanguard ETF With Taiwan Semiconductor, Samsung Electronics, SK Hynix, and ASML as Its 4 Largest Holdings ↗
International stock ETFs offer superior diversification, lower valuations, and higher yields than S&P 500 ETFs like VOO. 
Via The Motley Fool
Topics ETFs Stocks
Discover which dow jones stocks are making waves on Wednesday. ↗
Via Chartmill
These dow jones stocks are moving in today's session ↗
Via Chartmill
Stock Market Today: Big Banks Earn Billions, Bumble Soars on Buyout ↗
Via Chartmill
News headline image
J&J (JNJ) Q3 2026 Earnings Call Transcript ↗
Innovative Medicine drove 7.9% growth as revenue hit $25.4 billion. 
Via The Motley Fool
Topics Earnings
Explore the top gainers and losers within the dow jones index in today's session. ↗
Via Chartmill
These S&P500 stocks are moving in today's session ↗
Via Chartmill
News headline image
Why Johnson & Johnson Stock Dropped Today ↗
Johnson & Johnson beat earnings this morning. Then its stock price dropped. 
Via The Motley Fool
Topics Earnings
News headline image
Surgical Precision, Sustainable Returns: Johnson & Johnson Secures its Cash Flow Runway ↗
Johnson & Johnson posted Q3 revenue growth of 5.9% to $25.4 billion, raised guidance, and gained analyst support as its OTTAVA surgical system and talc settlement shape its long-term outlook. 
Via MarketBeat
Discover which dow jones stocks are making waves on Tuesday. ↗
Via Chartmill
Explore the top gainers and losers within the S&P500 index in today's session. ↗
Via Chartmill
News headline image
Stock Market Midday, Oct. 13: Bank Earnings and Chip Pressure Drive Mixed Trading ↗
Goldman Sachs gains on strong revenue while Johnson & Johnson stumbles on earnings miss, today, Oct. 13, 2026. 
Via The Motley Fool
Topics Earnings Stocks
News headline image
What Johnson & Johnson (JNJ) Said on Its Q3 Earnings Call ↗
Johnson & Johnson (NYSE:JNJ) reported third-quarter 2026 worldwide sales of $25.4 billion, up 6% operationally from a year earlier, as growth in its Innovative Medicine business offset... 
Via MarketBeat
Topics Earnings
These S&P500 stocks are gapping in today's session ↗
Via Chartmill
News headline image
Health Bellwether J&J Slumps As Middle East Conflict Hampers Medtech Sales ↗
Johnson & Johnson stock fell early Tuesday as the conflict in the Middle East weighted on medical device sales. 
Via Investor's Business Daily
News headline image
Want Passive Income for Life? Here Are 2 Dividend Stocks to Buy and Never Sell ↗
These companies have a long history of dividend growth. 
Via The Motley Fool
News headline image
Johnson & Johnson vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? ↗
Johnson & Johnson trades at a higher valuation with growing sales, while Pfizer's dividend yield is near 6% as patents expire from 2026 through 2030. 
Via The Motley Fool
Topics Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.